# US 10,117,866 B2 · Promoting axon regeneration in the adult CNS through control of protein translation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,866 B2
- Document ID: US10117866B2
- Status: Granted
- Kind: B2
- Application number: 14/244,065
- Filed: 2014-04-03
- Published: 2014-07-31
- Granted: 2018-11-06
- Earliest claimed: 2008-06-06
- Assignees: Children's Medical Center Corporation
- Applicants: Children's Medical Center Corporation
- Inventors: Zhigang He; Kevin Park; Kai Liu; Yang Hu
- Web page: https://patentgrep.com/patent/US10117866B2

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/28: Compounds containing heavy metals
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron.

## Claims

### Claim 1

A method for promoting survival of, and axon regeneration in a lesioned mature human neuron in vivo, wherein the lesion results from a traumatic spinal cord injury arising from physical force, comprising contacting the lesioned neuron with a therapeutically effective amount of a PTEN specific inhibitor to thereby promote survival of, and axon regeneration in the neuron.

### Claim 2 (depends on 1)

The method of claim 1, further comprising detecting the resultant promotion of the survival of, and axon regeneration in the neuron.

### Claim 3 (depends on 2)

The method of claim 2, wherein the detecting step is by an indirect assay of axon regeneration.

### Claim 4 (depends on 2)

The method of claim 2, wherein the detecting step is by a direct assay of axon regeneration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is administered locally at the neuron.

### Claim 6

A method for promoting axon regeneration in a lesioned mature human central nervous system (CNS) neuron in vivo, wherein the lesion results from a traumatic spinal cord injury arising from physical force, comprising contacting the neuron with a therapeutically effective amount of a PTEN specific inhibitor to thereby promote axon regeneration in the neuron.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neuron is in the spinal cord.

### Claim 8 (depends on 6)

The method of claim 6, wherein the inhibitor is administered locally at the neuron.

### Claim 9

A method for promoting axon regeneration in a lesioned mature human neuron in vivo, wherein the lesion results from acute spinal cord injury arising from physical force, comprising contacting the lesioned neuron with a therapeutically effective amount of a PTEN specific inhibitor to thereby promote axon regeneration in the neuron.

### Claim 10 (depends on 9)

The method of claim 9, wherein the inhibitor is administered locally at the neuron.